Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TIL
STRONG SELLInstil Bio, Inc. · Healthcare · United States · $50M · Avg Vol: $127K/d
10
StockRankGet insider-trade alerts
Q
26
V
36
M
27
P/E (TTM)
—
ROE
-37.1%
D/E
0.8x
Dividend %
—
COMPANY DESCRIPTION
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — |
| EPS | -34.40 | -24.00 | -11.39 | -10.70 | — | -6.88 |
| Shares | 6.5M | 6.5M | 6.5M | 6.8M | +4.3% | 6.8M |
| Debt | 79.9M | 86.1M | 86.9M | 85.2M | 2.2% | 85.2M |
| Equity | 363.6M | 225.8M | 169.4M | 113.9M | -32.1% | — |
| Op CF | -180.2M | -82.0M | -55.7M | -36.6M | — | -33.8M |
| Inv CF | 114.5M | 41.1M | 54.0M | 25.5M | — | — |
| Fin CF | 71.9M | 8.1M | 1.8M | 7.3M | — | — |
Loading 1Y...
PRICE (1Y)-5.9%
SMA 50SMA 200
Close
$7.66
RSI (14)
55.6
52W High
$33.83
From 52W High
0.2%
SCORE BREAKDOWN
Quality
26
ROIC
-33.4%20.5
ROE
-37.1%22.1
GP/Assets
—N/A
Op. Margin
0.0%40.3
FCF/Assets
-22.9%14.0
Piotroski
29.2
Int. Cover
-13.2x20.6
D/E Ratio
0.77x21.1
Current Ratio
39.87x98.9
Value
36
P/E (TTM)
—N/A
EV/EBITDA
-1.4x25.0
P/FCF
—N/A
P/B
0.5x96.2
P/S
—N/A
Div Yield
—N/A
Momentum
27
52W High %
23%3.2
RS 6M
6%74.8
SMA 50/200
0.75x10.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-113%3.6
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$50M
P/E (Forward)
-0.5x
Gross Margin
0.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TIL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TIL | Instil Bio, Inc.(you) | $50M | 10 | STRONG SELL |
| CNTX | Context Therapeutics Inc. | $53M | 10 | STRONG SELL |
| FLNA | Filana Therapeutics, Inc. | $58M | 9 | STRONG SELL |
| DWTX | Dogwood Therapeutics, Inc. | $55M | 9 | STRONG SELL |
| ATYR | aTyr Pharma, Inc. | $52M | 4 | STRONG SELL |
| CING | Cingulate Inc. | $67M | 13 | STRONG SELL |
| 4875.T | MediciNova, Inc. | $62M | 15 | STRONG SELL |
| ACRV | Acrivon Therapeutics, Inc. | $72M | 14 | STRONG SELL |
| KALA | KALA BIO, Inc. | $63M | 4 | STRONG SELL |
| GOSS | Gossamer Bio, Inc. | $77M | 7 | STRONG SELL |
Peer medians: ROE -21.2% · P/E 27.1x · Gross margin 44.5%